EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Home Study, Report Number 3. Retina 2016 Aug;36(8):1542-7
Date
06/01/2016Pubmed ID
27243927Pubmed Central ID
PMC4961546DOI
10.1097/IAE.0000000000000940Scopus ID
2-s2.0-84973160237 (requires institutional sign-in at Scopus site) 32 CitationsAbstract
PURPOSE: To determine the effectiveness of different monitoring modalities to detect incident neovascularization associated with age-related macular degeneration (AMD).
METHODS: Secondary analyses compared the rates of detecting incident neovascular AMD in prescheduled office visits versus office visits triggered by monitoring device or by symptom realization in a randomized trial evaluating home telemonitoring device plus standard care (device arm) versus standard care alone.
RESULTS: At prescheduled office visits, neovascular AMD was detected in 14/1927 visits (0.7%, 95% confidence interval [CI]: 0.4%-1.1%) and 14/1949 visits (0.7%, 95% CI: 0.3%-1.1%) in the device and standard care alone arms, respectively. Thirty-seven participants with neovascular AMD were detected in 318 office visits (11.6%, 95% CI: 8.1%-15.2%) triggered by device or symptom realization and 17 neovascular AMD in 65 office visits (26%, 95% CI: 15.5%-36.8%) triggered by symptom realization in the device and standard care alone arms, respectively. The home device strategy had a higher neovascular-AMD detection rate than prescheduled office visits (relative risk = 16.0 [95% CI: 8.8-29.3]). Neovascular AMD detected at triggered visits were associated with less vision loss from baseline in the device arm versus standard care alone arm (-3 letters vs. -11.5 letters, respectively, P = 0.03).
CONCLUSION: Telemonitoring may alter the management of patients with AMD and improve vision outcomes.
Author List
Chew EY, Clemons TE, Harrington M, Bressler SB, Elman MJ, Kim JE, Garfinkel R, Heier JS, Brucker A, Boyer D, AREDS2-HOME Study Research GroupMESH terms used to index this publication - Major topics in bold
AgedAged, 80 and over
Angiogenesis Inhibitors
Choroidal Neovascularization
Female
Humans
Male
Middle Aged
Monitoring, Ambulatory
Office Visits
Telemedicine
Vision Disorders
Visual Acuity
Visual Field Tests
Visual Fields
Wet Macular Degeneration
